Anti-angiogenic drugs, such as recombinant endostatin (RE), have been intensely studied to inhibit tumour angiogenesis in NSCLC, leading to mixed and often disappointing results in (pre)clinical trials. Here, COL18A1 is linked to non-small cell lung carcinoma.